Activation of the platelet-derived growth factor (PDGF) receptor tyrosine kinase induces tyrosine phosphorylation of Signal Transducer and Activator of Transcription (STAT) proteins. Since the PDGF receptor also activates the Src tyrosine kinase, it is possible that Src mediates tyrosine phosphorylation of STATs in PDGFtreated cells. Consistent with a role for Src in STAT activation, we found that a PDGF receptor juxtamembrane tyrosine residue required for Src activation is necessary and sucient for activation of STATs 1 and 3. To test the Src requirement further, we made other mutations in the PDGF receptor juxtamembrane region that increased or decreased Src binding. In epithelial and ®broblast cells, PDGF activated STAT1, 3 and 6 in the absence of detectable binding and activation of Src. In addition, PDGF induced c-myc RNA expression and DNA synthesis even though Src was not detectably activated. The activation of MAP kinase and the induction of c-fos gene expression both correlated with STAT but not Src activation by the receptor. We conclude that juxtamembrane tyrosine phosphorylation is necessary for both Src tyrosine kinase and STAT activation by the bPDGF receptor, but that both processes are regulated independently by this region.
Introduction
Members of the Src family of tyrosine kinases play important roles in regulating cell growth, differentiation and transformation. This family comprises at least eight members in mammals that share sequence homologies with c-Src; the ®rst cellular protein tyrosine kinase and oncogene described (Brown and Cooper, 1996; Thomas and Brugge, 1997) . Src is activated in response to various external stimuli and by various mechanisms. In the case of PDGF-treated cells, a subset of Src molecules is recruited to activated bPDGF receptors by binding of the Src SH2 domain to phosphorylated tyrosine residues within the juxtamembrane domain of the receptor (Mori et al., 1993) . This binding is thought to activate Src by displacing an intramolecular interaction between the Src SH2 domain and a C-terminal phosphorylated tyrosine residue (Cooper and Howell 1993) . Total cellular Src activity rises transiently 2 ± 4-fold within minutes after stimulation of resting cells with PDGF (Ralston and Bishop, 1985; Gould and Hunter, 1988) . The initial binding and activation of Src family members to the bPDGF receptor appears to be necessary for PDGF-induced DNA synthesis and expression of the c-myc gene (Twamley- Stein et al., 1993; Barone and Courtneidge, 1995) . Src family members may also regulate expression of genes through phosphorylation and activation of transcription factors known as STATs. Recently it was shown that an activated mutant of Src, v-Src, constitutively phosphorylates and activates STAT3, and that STAT3 phosphorylation is necessary for ecient transformation of cells by v-Src (Yu et al., 1995; Cao et al., 1996; Chaturvedi et al., 1997; Bromberg et al., 1998; Turkson et al., 1998) . The phosphorylation of STAT3 by v-Src suggests that normal cellular Src may also phosphorylate STAT3 and directly regulate transcription.
The family of STAT proteins was identi®ed during studies of cytokine-induced gene expression (Darnell, 1997) . Cytokine receptors lack intrinsic tyrosine kinase activity but are associated with cytoplasmic tyrosine kinases of the JAK family (Ihle and Kerr, 1995) . Upon cytokine receptor oligomerization, JAKs phosphorylate the receptor molecules on tyrosine. This allows the receptor to bind STATs through their SH2 domains (Heim et al., 1995; Stahl et al., 1995) . STATs are then phosphorylated by JAKs on a conserved tyrosine residue, which drives the subsequent events of STAT release, dimerization and nuclear translocation (Briscoe et al., 1996) . Alternative mechanisms of STAT activation by JAKs which involve JAK/STAT interaction without a cytokine receptor scaold have also been described (Fujitani et al., 1997) .
Growth factors that act through receptors with intrinsic tyrosine kinase activity also activate STAT family members. Less is known about the role of STATs in growth factor signaling than in cytokine signaling, but both growth stimulatory and inhibitory pathways are stimulated (Wagner et al., 1990; Chin et al., 1996; Su et al., 1997) . The mechanism of tyrosine phosphorylation of STATs in growth factor treated cells is also unclear. The tyrosine kinase activities of the PDGF and EGF receptor tyrosine kinases are required for activation of STATs by PDGF and EGF, respectively, but it is not known whether these receptors directly phosphorylate STAT proteins or do so via another protein tyrosine kinase(s). Indeed, JAK family members become activated in growth factor treated cells Vignais et al., 1997; Valgeirsdottir et al., 1998) . Through studies in mutant cell lines lacking individual JAK family members it was established that individual JAKs are dispensable for growth factor mediated STAT activation (Leaman et al., 1996; Vignais et al., 1996) . This is in contrast to cytokine signaling where usually at least one JAK is essential for STAT activation (MuÈ ller et al., 1993) . Thus for growth factor signaling, either JAKs are not involved or are redundant. Direct interaction of STAT proteins with receptor tyrosine kinases has been suggested, implying direct phosphorylation of STATs by the receptors; however proof of direct interactions in vivo is lacking (Fu and Zhang, 1993; Novak et al., 1996; David et al., 1996; Chen et al., 1997) .
In addition to the intrinsic receptor tyrosine kinase and JAKs, Src family kinases are also candidates to phosphorylate STATs in growth factor treated cells. We have made use of bPDGF receptor mutants to test whether Src activation is necessary for PDGF-BB dependent activation of STATs. Supporting the hypothesis that Src mediates PDGF-induced STAT activation, we found that out of all known phosphorylated tyrosine residues, only the two juxtamembrane tyrosine residues (Y579, Y581) were necessary and sucient for activation of STAT1 and STAT3. These same tyrosine residues were previously shown to mediate Src binding and activation (Mori et al., 1993) . However, further studies, making use of additional mutant receptors, showed that STAT activation could occur in the apparent absence of Src family kinase activation. Surprisingly, c-myc gene induction and DNA synthesis were also induced in the absence of detectable Src binding or activation by the mutant receptors. This suggests that the juxtamembrane region of the bPDGF receptor regulates both STATs and Src family kinases but does so by dierent mechanisms.
Results
Juxtamembrane tyrosines 579 and 581 of the bPDGF receptor are necessary and sucient for STAT1 and STAT3 activation To identify regions of the bPDGF receptor that are required for STAT activation, we tested a series of receptor mutants for their ability to activate STATs.
Wild type and mutant human bPDGF receptors were expressed in TRMP canine epithelial cells that lack endogenous binding sites for PDGF-BB (Kazlauskas and Cooper, 1989) . We analysed PDGF-induced STAT activation by electrophoretic mobility shift assay using the high anity SIE element derived from the c-fos promoter . This element binds homo-and heterodimers of STAT1 and STAT3 (Ru-Jamison et al., 1993; Sadowski et al., 1993; Silvennoinen et al., 1993) . Figure 1 shows that PDGF activated STAT1 and STAT3 in cells expressing the wild type PDGF receptor. Kinase activity of the PDGF receptor was required for STAT activation, as evident from the complete lack of SIE binding activity in cells expressing a kinase-inactive receptor mutant (mutant 635, Figure 1 ). Neither deletion of seven tyrosine phosphorylation sites within the kinase insert domain (KID) nor mutation of the C-terminal phosphorylation sites 1009 and 1021 to phenylalanine, individually or in combination, had any signi®cant eect on STAT activation by the PDGF receptor. Even combined mutation of C-terminal and kinase insert phosphorylation sites (KID/1009/1021) only partially reduced STAT activation. The only phosphorylation sites known to persist in this multiple mutant are Y857 in the kinase domain and Y579 and Y581 in the juxtamembrane region, suggesting that phosphorylation of these residues may be sucient for STAT activation. Indeed, Y579 appears to be necessary for STAT activation since a phenylalanine substitution at Y579 strongly inhibited STAT activation (Figure 1) . Mutation of Y581 also reduces STAT activation. Both tyrosine residues have been identi®ed as phosphorylation sites, and are important for Src family member binding and activation (Mori et al., 1993) .
PDGF receptor variants with altered Src binding capacities similarly activate STATs 1 and 3 in epithelial cells
The binding speci®city of the Src SH2 domain critically depends on the amino acid sequence immediately Cterminal to the phosphorylated tyrosine residue (Songyang et al., 1993; Waksman et al., 1993; Marengere et al., 1994; Alonso et al., 1995) . We exchanged the three residues C-terminal to Y579 (IYV) to either a poor (VNV) or to an optimized (EEI) Src SH2 binding sequence ( Table 1 ), predicting that these Figure 1 STAT activation in untreated and PDGF-treated epithelial cells expressing wild type or mutant PDGF receptors. TRMP cell lines expressing either wild type (wt) or mutant human bPDGF receptors were grown to con¯uence, serum-starved for 16 ± 18 h, and then left untreated or treated with PDGF-BB (100 ng/ml) for 10 min. Cells were collected and whole cell extracts prepared. Extracts (20 mg) were subjected to mobility-shift analysis with a 32 P-labeled SIE probe. The three speci®c STAT-DNA complexes are indicated. The mutants are as follows: K635R is a kinase-negative receptor, KID is a deletion of the kinase insert domain and removes all autophosphorylation sites in this region. Additional mutants are indicated by the speci®c autophosphorylation site or combination of sites that were mutated from Y to F. The mutant receptors demonstrating a loss of STAT activation (K635R, Y581F, Y579F) were expressed at equivalent or higher levels than the wild type receptor (not shown) mutations would respectively reduce or enhance binding and activation of Src family members by the receptor. The receptor variants were expressed in TRMP epithelial cells. All receptor variants were equally expressed, contained comparable amounts of phosphotyrosine upon ligand stimulation, and induced a similar pattern and strength of cellular protein tyrosine phosphorylation (Figure 2a) . Phosphotyrosine proteins at 45 and 42 kDa comigrate with ERK1 and ERK2 MAP kinase and were similarly phosphorylated by all mutants. A 25-kDa phosphoprotein was consistently phosphorylated at increased level in cells expressing the EEI mutant receptor and may represent a Src-speci®c substrate. None of the sequence alterations compromised the tyrosine kinase activity of the receptor.
To measure binding of Src to the mutant receptors, endogenous Src was precipitated with a polyclonal antiserum raised to the Src C-terminus, and the immunoprecipitates were analysed by anti-phosphotyrosine Western blot. The phosphorylated wild type bPDGF receptor associated with Src when cells were treated with PDGF ( Figure 2b , lanes 1 and 2). As expected, the Y579F point mutation prevented Src binding to the PDGF receptor ( Figure 2b , lanes 3 and 4). Introduction of the optimal Src SH2-binding sequence EEI signi®cantly enhanced PDGF-dependent binding of the receptor to Src (Figure 2b , lanes 5 and 6), whereas the VNV mutation abolished binding ( Figure 2b , lanes 7 and 8). Measuring the PDGF receptor/Src association by in vitro kinase assay supported these results (data not shown). None of the PDGF receptor mutations induced constitutive association with Src.
PDGF receptor mutants capable of binding Src also induced an increase in Src tyrosine phosphorylation and decrease in Src electrophoretic mobility ( Figure  2b ). Src tyrosine phosphorylation was increased and Src mobility was decreased following stimulation of wild type and EEI, but not Y579F or VNV, mutant receptors. N-terminal tyrosine and serine phosphorylation of Src has been shown to correlate with increased Src tyrosine kinase activity and to cause changes in electrophoretic mobility (Gould and Hunter, 1988) . This suggested that the dierences in binding of Src to 
Sequences from position 579 ± 585 of the human bPDGF receptor are shown. Changes in sequence compared to wild type are in bold. pY denotes phosphorylated tyrosine residues.
b The proposed binding of characteristics of Src to the juxtamembrane sequences are given based on published information (see text for details) Figure 2 Eects of juxtamembrane mutations on PDGF receptor functions in epithelial cells. (a) (Top panel) Protein phosphorylation. TRMP cell lines expressing PDGF receptor juxtamembrane variants or the empty expression vector were treated with PDGF-BB (50 ng/ml) for 15 min or left untreated and cytoplasmic extracts were prepared. Equal amounts of whole cell extract were separated by 10% SDS ± PAGE and analysed by Western blot using phosphotyrosine speci®c antibody 4G10 and enhanced chemiluminescence (ECL) reaction. Arrows point to inducible tyrosine phosphorylated proteins in the extract. (Bottom panel) Receptor expression. Equal amounts of extract protein were separated by 7.5% SDS ± PAGE and probed with a rabbit antiserum (2897) directed against the C-terminus of the PDGF receptor (Kazlauskas et al., 1991) . (b) Src association. TRMP cell lines expressing PDGF receptor variants were left untreated or treated with PDGF-BB (50 ng/ml) for 5 min, and Src was isolated by immunoprecipitation using rabbit antiserum 3060 (Cooper et al., 1986) . Immunocomplexes were separated by 7.5% SDS ± PAGE and analysed by Western blot using phosphotyrosine speci®c antibody 4G10. Arrows point to the PDGF receptor and Src, respectively. Asterisks denote unspeci®c signals that were also present in preimmunoprecipitates (not shown). (c) STAT activation. TRMP cell lines expressing PDGF receptor variants were left untreated or treated with PDGF-BB (50 ng/ml) for 15 min and nuclear extracts were prepared. Equal amounts of nuclear extract protein were subjected to mobility shift analysis using a 32 Plabeled SIE-probe PDGF-induced STAT activation C Sachsenmaier et al the receptors caused changes in ligand-induced posttranslational modi®cation of Src.
We tested the activation of STATs by the PDGF receptor variants using the electrophoretic mobility shift assay on the SIE (Figure 2c ). Despite its inability to bind Src, the VNV receptor variant was fully competent to activate STAT1 and STAT3 (Figure 2c , lanes 1 and 2). Basal SIE binding activity in these cells was slightly increased (lane 1). The EEI variant, which bound Src much better than the wild type receptor, was not altered in its ability to activate STATs ( Figure  2c, lanes 3 and 4) . PDGF dose-response curves did not reveal any increase in the STAT activation at low doses of PDGF (data not shown). These data showed that despite dierences in binding Src, the receptor variants were equally competent to stimulate STATs. This suggested that binding (and presumably activation) of Src tyrosine kinases is not necessary for PDGFinduced activation of STAT1 and STAT3.
Activation of STATs in ®broblasts in the absence of detectable activation of Src tyrosine kinases
Studies on v-Src-induced activation of STAT3 were mostly performed in ®broblastic cells (Yu et al., 1995; Cao et al., 1996) . We were unable to detect constitutive activation of STATs in TRMP epithelial cells overexpressing a Y527F activated mutant of c-Src (data not shown), suggesting that ®broblasts and epithelial cells might dier in STAT activation pathways. Since most ®broblasts express endogenous PDGF receptors, we designed chimeric receptors in which the extracellular ligand binding domain of the human bPDGF receptor was replaced with that of the human colony stimulating factor-1 (CSF-1) receptor (Figure 3a ) (Sherr et al., 1985) . This allowed us to speci®cally stimulate the chimeric receptor (CSF/PDGF receptor) with human CSF-1 without activating endogenous PDGF receptors (Roussel et al., 1987) . When expressed in NIH3T3 cells, the CSF/PDGF receptor chimera initiated identical STAT activation ( Figure  3b ), protein tyrosine phosphorylation (Figure 4a ) and mitogenic response (Figure 6b ) to the endogenous PDGF receptor. All CSF-1-induced responses strictly depended on the expression of the chimeric receptors and signaling through the endogenous PDGF receptor was not aected, proving the functionality and speci®city of the CSF/PDGF receptor chimera.
To test the eects of the juxtamembrane sequence changes, mutations were introduced into the CSF/ PDGF receptors and expressed in NIH3T3 cells (Figure 4) . Expression levels were equal by FACS analysis (not shown), and all receptors became tyrosine phosphorylated upon CSF-1 stimulation (Figure 4a ). The VNV and EEI mutant CSF/PDGF receptors showed slightly decreased and increased phosphorylation, respectively, and an unknown protein was hyperphosphorylated on tyrosine in EEI receptor expressing cells (p36, Figure 4a ).
To determine whether sequence changes in the juxtamembrane region of the CSF/PDGF receptor chimera aected binding of Src family members, we used antibody cst.1 (Kypta et al., 1990) to immunoprecipitate the three Src family members Src, Fyn and Yes from NIH3T3 cells. Western blot analysis using phosphotyrosine-speci®c antibodies showed that the The sequence alterations within the juxtamembrane region were introduced into the CSF/PDGF receptor chimera. (b) STAT activation. NIH3T3 cell lines expressing the wild type CSF/PDGF receptor chimera (CSF/PDGFR) or the empty expression vector were stimulated with 50 ng/ml human CSF-1 (c), 50 ng/ml human PDGF-BB (P) or the same volume of diluent (co) for 15 min followed by preparation of nuclear extracts. Equal amounts of nuclear extracts were analysed by mobility-shift analysis using either the hSIE (left panel) or the immunoglobulin heavy chain germ line e promoter (Ie, right panel) (Patel et al., 1996) as a probe Y579F and VNV mutations reduced ligand-induced coprecipitation of CSF/PDGF receptors with Src family members (Figure 4b , lanes 3 ± 6) relative to wild type (lanes 1 and 2). The EEI mutation slightly reduced coprecipitation (lanes 7 and 8) relative to wild type. However, use of a Fyn-speci®c antibody instead of cst.1 showed equal precipitation of EEI and wild type receptors, and a Src-speci®c antibody showed increased precipitation of the EEI mutant (data not shown). No VNV or Y579F mutant receptor was detected in either the Fyn-or Src-speci®c antibody immunoprecipitates. These results that Src family members bind dierently to the EEI mutant receptors, but that the VNV mutation inhibits binding of Src and Fyn.
To measure Src activation by wild type and mutant CSF/PDGF receptors, cst.1 immunoprecipitates were incubated with [g 32 P]ATP and an exogenous substrate, enolase (Cooper et al., 1984) . CSF-1 treatment increased Src autophosphorylation and enolase phosphorylation (Figure 4c, lanes 1 and 2) . CSF-1-induced Src kinase activity was reduced by both the Y579F and the VNV mutations, concomitant with a loss of interaction with Src ( Figure 4c , lanes 3 ± 6), while EEI receptors bound to and activated Src (Figure 4c , lanes 7 and 8). The phosphorylation of associated CSF/PDGF receptors in the cst.1 immunoprecipitates (Figure 4c ) approximately correlated with the quantities of receptors detected by Western blotting ( Figure  4b ). These data show that the activation pro®le of Src family members closely re¯ects their ability to interact with the CSF/PDGF receptor, and that the VNV mutation inhibits Src tyrosine kinase activation in NIH3T3 cells.
STAT1 and 3 activation were measured using the SIE probe, and STAT6 activation was measured with an immunoglobulin probe, (Patel et al., 1996) . The Y579F mutation strongly reduced STAT1, 3 and 6 DNA binding activity (Figure 4d, lanes 3 and 4) . Despite its inability to bind and activate Src family members, the VNV CSF/PDGF receptor variant was fully competent to activate STAT1, 3 and 6 (Figure 4d , lanes 5 and 6). The EEI receptor variant also activated these STAT members, rather more eciently than the wild type CSF/PDGF receptor (lanes 7 and 8).
In summary, the binding and activation of Src tyrosine kinases by the PDGF receptor did not correlate with ligand-induced activation of STATs.
Activation of MAP kinase and c-fos RNA accumulation by CSF/PDGF receptor variants
We tested the eects of the juxtamembrane sequence alterations on ligand-induced MAP kinase activation and c-fos mRNA accumulation in NIH3T3 cells NIH3T3 cell lines expressing juxtamembrane mutant CSF/PDGF receptor chimeras or the empty vector were treated with human CSF-1 (50 ng/ml) or diluent for 5 min, and equal amounts of total extract protein were separated by 10% SDS ± PAGE and subjected to anti-phosphotyrosine Western blot analysis using antibody 4G10. Arrows indicate inducible tyrosine phosphorylated proteins. (b) Src association. Src family kinases were isolated by immunoprecipitation using the cross-reactive rabbit antiserum cst.1 (Kypta et al., 1990) . Immunocomplexes were separated by 10% SDS ± PAGE and subjected to anti-phosphotyrosine Western blot analysis using antibody 4G10. (c) Src activity. Anti cst.1 immunocomplexes from (b) were incubated with acid-treated enolase and [g 32 P]ATP, separated by 10% SDS ± PAGE and analysed by autoradiography. (d) STAT activation. Cells were stimulated with human CSF-1 (50 ng/ml) or diluent for 15 min. Equal amounts of nuclear extracts were subjected to mobility shift analysis using the hSIE (upper panel) or Ie (lower panel) probe expressing CSF/PDGF receptors. MAP kinases have been implicated in phosphorylation of STAT proteins on serine and thereby regulating transactivation by and tyrosine phosphorylation of STATs (Wen et al., 1995; Chung et al., 1997) . Activation of the MAP kinases ERK1 and ERK2 was inferred from the appearance of electrophoretically-retarded, phosphorylated forms (Anderson et al., 1990) . Figure 5a shows that ERK activation was detected with Y579F, VNV and EEI mutant CSF/PDGF receptors. The extent of ERK activation was greatest for EEI mutant receptor, less for VNV and wild type receptors, and least for the Y579F mutant receptor.
We also measured c-fos RNA accumulation in response to activation of the CSF/PDGF receptor chimera (Figure 5b) . STATs have been shown to participate in the transcriptional activation of c-fos reporter genes in response to growth factor stimulation of cells (Wagner et al., 1990; Hill and Treisman, 1995) and during development (Robertson et al., 1995) . Similar to the eects on MAP kinase phosphorylation, c-fos RNA induction was greatest for EEI mutant receptor, less for VNV and wild type receptors, and least for Y579F mutant receptor (Figure 5b ). These data correlated with the eects of the juxtamembrane mutations on ligand-induced STAT activation ( Figure   Figure 5 Activation of MAP kinases and c-fos gene expression by CSF/PDGF receptor variants. (a) MAP kinase analysis. NIH3T3 cell lines expressing CSF/PDGF receptor variants were treated with 10 ng/ml human CSF-1 for 10 or 40 min. Controls (co) were treated with diluent for 10 min. Cells were harvested, lysed in RIPA buer, separated by 10% SDS ± PAGE and analysed by Western blot analysis using rabbit anti-ERK2 serum (1913) (Posada et al., 1991) . (b) c-fos expression. NIH3T3 cell lines expressing CSF/PDGF receptor variants were treated with 25 ng/ml human CSF-1 for 45 or 180 min. Controls (co) were treated with diluent for 45 min. After treatment cells were harvested and polyA + RNA was prepared. 5 mg of RNA were separated by formaldehyde-agarose gel electrophoresis, blotted onto Nylon membrane and probed simultaneously with probes for c-fos and glyceraldehyde 3-phosphate dehydrogenase (gapdh) c-myc induction and DNA synthesis occur in cells lacking detectable PDGF-stimulated Src activity PDGF-induced DNA-synthesis and c-myc RNA accumulation are inhibited by Src antibody injection or dominant-negative mutants in NIH3T3 cells . We tested the eects of the juxtamembrane mutations of the bPDGF receptor on these responses using the CSF/PDGF receptor chimera in NIH3T3 cells. Despite the strong eects on Src activation, all receptor mutants induced c-myc RNA accumulation at 45 min after ligand treatment (Figure 6a ). The accumulation of c-myc RNA at 180 min after stimulation was increased by the Y579F and EEI mutations (Figure 6a ). Thus, there is no simple relationship between the extent or duration of c-myc induction and the level of Src activation by the mutant receptors. In addition, all CSF/PDGF receptor variants initiated comparable DNA-synthesis in response to treatment of cells with CSF-1 ( Figure  6b) . In all cases, maximal response to CSF-1 was comparable to the stimulation by fetal bovine serum. These data indicate that activation of Src tyrosine kinases by the bPDGF receptor is not necessary for ligand-induced c-myc expression and mitogenic response.
Discussion
We made use of PDGF receptor mutants to investigate the mechanism of STAT activation by the bPDGF receptor. Mutation of phosphorylation sites in the kinase insert and C-terminus of the bPDGF receptor did not prevent STAT1 and 3 activation in response to PDGF, whereas mutation of two juxtamembrane tyrosine residues (Y579 and Y581) inhibited STAT1 and 3 activation. This suggests that Y579 and Y581 mediate STAT activation. Because these residues also mediate binding and activation of the Src family of protein tyrosine kinases (Mori et al., 1993) , these results were consistent with a role for Src family members in PDGF-induced STAT activation. However, substitution of receptor residues 580 ± 582 with the sequence VNV inhibited Src binding and activation without preventing activation of STAT1, 3 or 6. Activation of STATs 1 and 3 but not Src was also observed when receptor residues 580 ± 582 were replaced with the sequence ENP (C Sachsenmaier, unpublished results). These results show that STATs can be activated by PDGF in the absence of growth factor-stimulated Src activity.
This raises the question of which tyrosine kinase is responsible for STAT activation in PDGF-treated cells. By inference from cytokine receptors, JAKs are obvious candidates. JAKs are activated in PDGFtreated cells (Vignais et al., 1996; Valgeirsdottir et al., 1998) . However, the evidence from mutant cell lines indicates that no single JAK is required for PDGF signaling (Vignais et al., 1996) . One possibility is that the JAKs exhibit redundancy when activated by the PDGF receptor, even though they are non-redundant when activated by cytokine receptors. It is alternatively possible that the PDGF receptor activates a cytokine receptor, which then uses a speci®c JAK to activate STATs. A precedent is provided by the PDGF receptor relative, cKit, which phosphorylates the erythropoietin receptor (Wu et al., 1995) . In this scenario, JAKs could be redundant for PDGF signaling if the PDGF receptor activates more than one cytokine receptor, each working through dierent JAKs to redundantly activate STATs.
It is also possible that the PDGF receptor directly phosphorylates STATs. This possibility is the hardest to exclude since mutations that inhibit the receptor kinase inhibit all known receptor-mediated events. Recently, Volgeirsdottir et al. (1998) reported that STAT5 might bind to tyrosine phosphorylation sites in the bPDGF receptor. They showed that phosphopeptides containing Y579/581 and Y775 are direct in vitro binding sites for the STAT5 SH2 domain. This is consistent with mutagenesis experiments, showing that STAT5 activation in vivo is reduced by mutation of Y579, Y581 or Y775 (Volgeirsdottir et al., 1998) . Therefore they proposed that STAT5 might need to bind to the receptor to be activated. On the other hand, our experiments with STATs 1, 3 and 6 suggest that any SH2-domain protein involved in STAT activation would have to recognize VYI (wild type), VNV and EEI sequences C-terminal to the phosphorylated tyrosine. Such a diversity of ligands for a single SH2 domain seems improbable. Another tyrosine kinase receptor, the EGF receptor, directly binds STATs but the signi®cance is again unclear. The EGF receptor directly interacts in vitro with the STAT1 SH2 domain, in a phosphorylation-dependent manner, yet all known phosphorylation sites in the EGF receptor are dispensable for EGF-induced STAT activation in vivo (David et al., 1996) . This suggests that STAT activation does not require STAT binding to the EGF receptor. The possibility that STAT binding to the PDGF and EGF receptor is not necessary for activation suggests distinct mechanisms of STAT activation by cytokine receptors and receptor tyrosine kinases.
Our results do not exclude the possibility that Src protein, as opposed to kinase activity, causes STAT activation. For example, Src could provide a docking site for JAKs or STATs during PDGF-stimulated STAT tyrosine phosphorylation. Indeed, STAT3 and JAK1 are constitutively tyrosine phosphorylated and complexed with Src in cells transformed by activated, mutant Src (Cao et al., 1996; Campbell et al., 1997) . To test for a role for Src family members in STAT activation, we have performed preliminary experiments in cell lines derived from mouse embryos that lack the Src family members Src, Fyn and Yes (Richard Klinghoer, C Sachsenmaier, JA Cooper, Philippe Soriano, unpublished results). STATs 1 and 3 are still activated by PDGF in these cells, making it unlikely that Src family proteins are involved.
Our results with chimeric receptors in NIH3T3 cells also address the signaling pathways that induce c-fos and c-myc gene expression and DNA synthesis. There is a good correlation between STAT activation and c-fos mRNA expression in response to ligand treatment. This is in agreement with studies on transfected or integrated c-fos promoter-dependent reporter genes, which show that STATs participate in regulating c-fos gene expression (Wagner et al., 1990; Hill and Treisman, 1995; Robertson et al., 1995) . However, there is also a good correlation between c-fos induction and MAP kinase activation ( Figure 5 ). MAP kinase is known to activate c-fos expression independently of STATs (Marais et al., 1993) . Therefore, our results do not distinguish the importance of STAT and MAP kinase pathways for c-fos induction in PDGF-treated cells. However, the VNV mutation dissociates Src activation from STAT, MAP kinase, and c-fos activation. This corroborates conclusions from antibody-injected NIH3T3 cells , indicating that c-fos induction occurs when Src is inhibited. On the other hand, results with receptor mutants con¯ict with antibody-injection experiments with regard to a role for Src in c-myc induction and DNA synthesis. We found that Y579F and VNV mutant CSF/PDGF receptors induced DNA synthesis and c-myc induction in the absence of Src activation, while Courtneidge and colleagues found that injected anti-Src antibodies or dominant negative mutants inhibited DNA synthesis and c-myc induction by endogenous PDGF receptors (Twamley-Stein et al., 1993; Barone and Courtneidge, 1995; Roche et al., 1995) . Our results agree with those of DeMali and Kazlauskas (1998) , who found that chimeric PDGF receptors that do not activate Src are nevertheless capable of inducing DNA synthesis. It is possible that the microinjection approach not only inhibits ligandinduced Src tyrosine kinase activity but also interferes with possible later activation of Src. Antibody injection several hours after PDGF stimulation inhibited DNA synthesis (Twamley-Stein et al., 1993) , and at these times the PDGF receptor juxtamembrane region may no longer be necessary for Src activation. Experiments using cells that lack Src, Yes and Fyn are in progress to clarify this possibility.
It is intriguing that the juxtamembrane region of the bPDGF receptor regulates both Src activation and STAT activation. The juxtamembrane domains of receptor tyrosine kinases have important but poorlyunderstood regulatory functions (Myles et al., 1994; Herbst et al., 1995; Hirota et al., 1998) . Studies are underway aiming at the identi®cation of the signaling components that link the juxtamembrane region of the PDGF receptor to STAT activation. This will hopefully lead to insights into the mechanisms of STAT activation and their role in signaling by other growth factor receptors.
Materials and methods

PDGF and CSF/PDGF receptor constructs
Human bPDGF receptor mutants that replace phosphorylation sites in the C-terminus have been described (Kashishian and Cooper, 1993) . These were combined with deletion mutants of the kinase insert domain (Kashishian et al., 1992) , removing sequences from aa 707 ± 794 of the receptor. Tyrosine to phenylalanine mutants of Y579 and Y581 were a kind gift of Lena Claesson-Welsh and were moved into the pLXSN retroviral expression vector (Miller and Rosman, 1989) . All mutants were stably expressed in TRMP canine epithelial cells as described in Kashishian et al. (1992) . The juxtamembrane sequence of the receptor was altered at positions 580 ± 582 using standard protocols (Kunkel, 1985) . The following oligonucleotides were used to change the wild type sequence of the receptor to either VNV (5'-CATGGGGTCCACGTTAACGTACTCATGGCCGTCAA-GCTCAC-3'; HincII site introduced) or to EEI (5'-CAT-GGGATCGATTTCTTCGT ACTCATGGCCGTCAGAGC-TCAC, ClaI site introduced). Site directed mutagenesis was performed on single stranded DNA derived from the plasmid pRR4 and the respective variants were moved into pLXSN as described (Kashishian et al., 1992) . The sequence alterations were con®rmed by sequencing.
To construct the CSF/PDGF receptor chimera, the extracellular ligand binding domain of the human CSF-1 receptor from position 1 ± 512 (Sherr et al., 1985) was ampli®ed by PCR using the primers 5'-GGAATTCGAGGC-CATGGGCCCAGGAGTTCTG-3' and 5'-CCGCTCGAGA-TACGCGTCTCATCCGGGGGATGCGT-3', cut with EcoRI and XhoI and moved into EcoRI/XhoI-cut pLXSN vector, yielding pLXSN-CSFRex. The transmembrane and cytoplasmic domains of the human bPDGF receptor from aminoacid 532 ± 1107 (Claesson-Welsh et al., 1988) were ampli®ed by PCR using the primers 5'-GGCGAC-GCGTGTGGTGGTGATCTCAGCC-3' and 5'-GCGGTC-GACTGAGTTCCCTGGGGGAAC-3', cut with MluI and SalI and moved into MluI/XhoI-cut pLXSN-CSFRex, yielding pLXSN-CSF/PDGFR. The Y579F, VNV and EEI PDGF receptor variants were moved into the chimeric background, accordingly.
Establishment of stable cell lines
The various pLXSN-based expression plasmids for the PDGF receptor, the CSF/PDGF receptor chimera and its variants were cotransfected with an amphotropic packaging vector (Afar et al., 1994) into 293T human embryonic kidney cells using a standard calcium phosphate coprecipitation protocol. Fresh DME medium with 10% fetal bovine serum (FBS) was added 24 and 48 h after transfection and recombinant viruses were collected over a period of 24 h after the second addition of fresh medium. The viruscontaining medium was ®lter sterilized and added to TRMP or NIH3T3 cells in the presence of 4 mg/ml polybrene for 24 h. Stable expressing cells were selected as pools in 1 mg/ml G418 (Gibco BRL) and routinely maintained in 0.1 ± 0.2 mg/ ml G418. The expression of the receptors were tested by Western blot analysis (TRMP cells) and FACS analysis (NIH3T3 cells), the latter by using a polyclonal antiserum directed against the extracellular ligand binding domain of the human CSF-1 receptor (a kind gift of L Rohrschneider).
Immunoprecipitation of Src
Cells were washed twice with ice cold PBS, 1 mM Na 3 VO 4 , 5 mM NaF and lysed on ice in 1 ml NP-40 buer (10 mM HEPES-KOH, pH 7.4, 1% NP-40, 2 mM EDTA, 50 mM NaF, 0.2 mM Na 3 VO 4 , 0.1% b-mercaptoethanol, 1% aprotinin, 1 mM PMSF). After centrifugation for 20 min at 13 000 g (48C) the supernatant was precleared with 25 ml (50% v/v) formalin-®xed S. aureus (pansorbin; Calbiochem, Inc.) plus 2 ml preimmune serum for 60 min at 08C. Precleared supernatants were incubated with 2 ml anti Src serum (3060) (Cooper et al., 1986) and 25 ml pansorbin for 60 min at 08C. The immunoprecipitates were washed four times with 1 ml NP-40 buer and resuspended in 25 ml 16SDS ± PAGE sample buer and separated by SDS ± PAGE. Immunoprecipitation of Src, Fyn and Yes using antibody cst.1 (a kind gift from S Courtneidge) and in vitro kinase assay using enolase was essentially done as described in Kypta et al. (1990) and Cooper et al. (1984) .
Electrophoretic mobility shift assay
Cells were washed once with PBS, 1 mM Na 3 VO 4 , 5 mM NaF (08C), transferred into a microcentrifuge tube and pelleted for 10 s. The cells were gently resuspended in 400 ml hypotonic buer (20 mM HEPES-KOH, pH 7.9, 20 mM NaF, 1 mM Na 3 VO 4 , 1 mM Na 4 P 2 O 7 , 0.4 mM microcystin, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 1 mg/ml leupeptin, 0.1% aprotinin, 0.2% Triton X-100) by stirring with a micropipet tip and¯icking. After incubating on ice for 15 min, the swollen cells were pelleted as above, and the supernatant was transferred into fresh tubes (cytoplasmic extract). The pellet (nuclei) was resuspended in 30 ± 50 ml of high salt buer (hypotonic buer without Triton X-100 and with 420 mM NaCl and 20% glycerol) and incubated on ice for 20 min. The nuclei were pelleted for 2 min in a microcentrifuge at full speed at 48C and the supernatant (nuclear extract) was used immediately or stored at 7708C. The cytoplasmic extract was adjusted to 120 mM NaCl, centrifuged for 20 min at full speed and 48C, supplemented with 20% glycerol and stored at 7708C. Whole cell extracts were prepared using high salt buer containing 0.2% Triton X-100. For EMSA two complementary single-stranded oligonucleotides comprising the high anity SIE sequence of the human c-fos promoter (Wagner et al., 1990 ) (5'-TCG-ACCATTTCCCGTAAATC-3'; 5'-TCGAGATTTACGGGA-AATGG-3') were annealed and radiolabeled using a 32 P-dCTP and Klenow fragment of DNA Polymerase I (Boehringer Mannheim). 2610 4 ± 1610 5 Cherenkov c.p.m. were incubated with 3 ± 5 mg of nuclear extract protein, separated by non-denaturing PAGE and analysed by autoradiography as described in Sadowski and Gilman (1993) .
Poly (A) + RNA isolation and Northern blot analysis
Poly (A) + RNA isolation and hybridization with c-fos and gapdh-speci®c cDNA probes was as described in Stein et al. (1992) . As a probe for c-myc-speci®c RNA we used a ClaI/ EcoRI fragment of pBS-myc (Hann et al., 1988) .
[
H]thymidine incorporation assay
Cells were seeded sparingly into 12 well plates, grown to con¯uence and serum starved in medium containing 0.1% FBS for 24 ± 48 h. Ligand was added followed by addition of [
